MetaCap

Corvus Pharmaceuticals Inc. (CRVS)

NASDAQ: CRVSHealth CareBiotechnology: Pharmaceutical PreparationsUSD

9.67-0.34 (-3.40%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CRVS stock chart

Technical analysis

Key statistics

All statistics
Market cap
$815.69M
EPS (TTM)
-$0.72
52-week range
6.39 – 26.95
Day range
9.56 – 10.03
Volume / Avg
927.52K / 1.05M
Beta
—

52-week range

$6.39$26.95

CRVS stock today

Corvus Pharmaceuticals (CRVS) closed at $9.67 on Nov 20, down 3.40% (-$0.34), versus the S&P 500's 3.70% decline. At this level, CRVS sits near the bottom of its 52-week range of $6.39 to $26.95: 64.1% below the high, set on Jan 23, 2026 and 51.3% above the low. CRVS is up 25.6% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 12.8%.

Corvus Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$0.72), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Corvus Pharmaceuticals

Company profile

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1 clinical trial for the treatment of non-small cell lung cancer.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Richard A. Miller M.D.
Headquarters
South San Francisco, CA
Employees
37
IPO year
2016

Financial highlights

Full financials

Corvus Pharmaceuticals reported a net loss of $15.3 million, compared with a loss of $62.3 million a year earlier. Diluted earnings per share came in at -$0.53.

Corvus Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2021FY 2021
Revenue—————
Growth—————
Net income$-15.28M$-62.29M$-27.03M$-41.31M$-43.24M
EPS (diluted)$-0.53$-1.02$-0.56$-0.89$-1.03

Analyst forecast

Forecast

Consensus (6 analysts)

strong_buy

Avg. price target

$31.50+225.75%

  • Strong buy 1
  • Buy 5
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $27.00High $42.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.12 vs $-0.21
Surprise
+42.86%

CRVS news

All CRVS news

Corvus Pharmaceuticals peers

Health Care sector
CRVS peer companies
CompanyPrice% ChgMarket capCompare
PHARPharming Group N.V. ADS11.54-5.10%$816.78Mvs CRVS
VSTMVerastem Inc.6.33-7.73%$797.67Mvs CRVS
SNDXSyndax Pharmaceuticals Inc.8.72-4.49%$785.05Mvs CRVS
IRWDIronwood Pharmaceuticals Inc. Class A4.70-0.21%$778.09Mvs CRVS
MTRIMentari Therapeutics Inc.14.70-3.57%$856.94Mvs CRVS
LTGOLatigo Biotherapeutics Inc.13.00-1.81%$861.89Mvs CRVS
COLLCollegium Pharmaceutical Inc.24.72-1.94%$768.18Mvs CRVS
ORICOric Pharmaceuticals Inc.7.36-4.42%$764.94Mvs CRVS

Indexes, lists and sector

Corvus Pharmaceuticals stock FAQ

What is Corvus Pharmaceuticals's stock price today?

CRVS last traded at $9.67 as of Nov 20, 4:00 PM EST, down 3.40% on the day. Prices are delayed at least 15 minutes.

Who is Corvus Pharmaceuticals's CEO?

Dr. Richard A. Miller M.D. is the chief executive officer of Corvus Pharmaceuticals Inc., which has about 37 employees.

What is the CRVS 52-week high?

The 52-week high for CRVS is $26.95 and the 52-week low is $6.39. The stock is currently 64.1% below its high.

Compare CRVS